News

NEW YORK, NY, June 30, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million

NEW YORK, NY, June 8, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43 rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET.

NEW YORK, NY, May 23, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. ET. The webcast will be accessible from Royalty

NEW YORK, NY, May 17, 2022 – Royalty Pharma plc (Nasdaq: RPRX) will host its inaugural Investor Day in New York City today. Royalty Pharma’s management team will provide an update on the company’s capital deployment

Establishes Mount Sinai-Royalty Pharma Alliance for Health Equity Research in collaboration with the Institute for Health Equity Research Alliance will support innovative, sustainable initiatives and policies that address systemic inequities in health care NEW YORK, NY, May 16, 2022 - Royalty

NEW YORK , NY,  May 05, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).

NEW YORK, NY, April 18, 2022 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on June 15, 2022, to shareholders of record at the close of business on May

NEW YORK, NY, April 13, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY and RYE BROOK, NY, March 28, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced a charitable commitment totaling $7.5 million to The Leukemia & Lymphoma Society (LLS), a global leader in the fight against blood cancer.

NEW YORK, NY, March 3, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 8, 2022 at 11:10 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at